Peptide Database

NNC 26-0161

Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist. Unlike other GHRPs, it stimulates GH release with high selectivity — producing minimal cortisol, ACTH, or prolactin elevation. It is among the most studied GHRPs for its clean GH pulse profile, making it a preferred research peptide for GH axis studies with reduced side effect concern.

Bremelanotide · Vyleesi

PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist, FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through MC3R and MC4R receptors in the hypothalamus to initiate sexual arousal, making it effective for psychological as well as physiological sexual dysfunction. Research also explores applications in male erectile dysfunction.

Ozempic · Wegovy

Semaglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Ozempic, Rybelsus) and obesity (Wegovy). By mimicking the incretin hormone GLP-1, it enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central hypothalamic pathways. Landmark trials demonstrate up to 15–17% body weight reduction and significant cardiovascular mortality benefit.

Mounjaro · Zepbound

Tirzepatide is the first dual GIP/GLP-1 receptor agonist, approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). By co-activating both incretin receptors, it achieves superior glycemic control and weight reduction compared to GLP-1 monotherapy — SURMOUNT trials showed up to 22.5% body weight reduction. It represents a new class of metabolic peptide therapeutics with broad cardiovascular and metabolic benefits.